Literature DB >> 1531168

Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study.

E A Walker1, W J Katon, R P Jemelka, P P Roy-Bryne.   

Abstract

The purpose of this investigation is to determine if the high prevalence rates of major depression, panic disorder, and agoraphobia found in tertiary-care studies of irritable bowel syndrome and medically unexplained gastrointestinal symptoms are also found in the general population. Structured psychiatric interviews on 18,571 subjects from the NIMH Epidemiologic Catchment Area (ECA) Study were reviewed for prevalence of gastrointestinal distress symptoms and selected psychiatric disorders. Medically unexplained gastrointestinal symptoms had a high prevalence in the general population (6-25%). When compared with those reporting no gastrointestinal symptoms, subjects who report at least one of these symptoms were significantly more likely to have also experienced lifetime episodes of major depression (7.5% vs 2.9%), panic disorder (2.5% vs 0.7%), or agoraphobia (10.0% vs 3.6%). Subjects with two gastrointestinal symptoms had even higher lifetime rates of depression (13.4%), panic (5.2%), or agoraphobia (17.8%). Lifetime rates of affective and anxiety disorders in the general population are higher in subjects with gastrointestinal symptoms compared with subjects without gastrointestinal symptoms. An even higher prevalence of affective and anxiety disorders is found in patients with medically unexplained gastrointestinal symptoms in tertiary-care clinics. Future studies are needed in primary-care populations where prevalence rates of psychiatric illness are probably intermediate between those of the general population and tertiary care.

Entities:  

Mesh:

Year:  1992        PMID: 1531168     DOI: 10.1016/0002-9343(92)90133-v

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  34 in total

Review 1.  Is there a SERT-ain association with IBS?

Authors:  M Camilleri
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

2.  Health care seeking for abdominal bloating and visible distention.

Authors:  X Jiang; G R Locke; A R Zinsmeister; C D Schleck; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2009-06-25       Impact factor: 8.171

3.  Evidence of overlapping genetic diathesis of panic attacks and gastrointestinal disorders in a sample of male twin pairs.

Authors:  Mark W Logue; Sarah R Bauver; William S Kremen; Carol E Franz; Seth A Eisen; Ming T Tsuang; Michael D Grant; Michael J Lyons
Journal:  Twin Res Hum Genet       Date:  2011-02       Impact factor: 1.587

Review 4.  Trauma and the gut: interactions between stressful experience and intestinal function.

Authors:  R Stam; L M Akkermans; V M Wiegant
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 5.  [Functional gastrointestinal disorders].

Authors:  Gabriele Moser
Journal:  Wien Med Wochenschr       Date:  2006-08

Review 6.  Physiological genomics of antidepressant targets: keeping the periphery in mind.

Authors:  R D Blakely
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 7.  New insights into the psychosocial aspects of irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Curr Gastroenterol Rep       Date:  2003-08

8.  Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes.

Authors:  Ami D Sperber; Roy Dekel
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

9.  Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity.

Authors:  S H Park; E J Videlock; W Shih; A P Presson; E A Mayer; L Chang
Journal:  Neurogastroenterol Motil       Date:  2016-04-08       Impact factor: 3.598

Review 10.  Nausea: a review of pathophysiology and therapeutics.

Authors:  Prashant Singh; Sonia S Yoon; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.